Hector Cameron

Hector Cameron is a Managing Partner of Lancaster Capital, a small Glasgow-based early-stage venture capital firm founded in 2012. Public databases (Tracxn, PitchBook) describe Lancaster Capital as a two-partner outfit, with Cameron serving as Managing Partner alongside co-founder Nick Sarris, listed as Founder & Director. The firm invests in seed-stage UK companies, concentrated in life sciences and enterprise software, and has historically syndicated its deals with other Scottish investors.

An important correction to the stub data: the supplied affiliation, email, and phone tie Hector Cameron to Kelvin Capital, a separate Glasgow angel/syndicate firm. Research shows Cameron is not a member of Kelvin Capital's team — Kelvin Capital's principals are chairman Stuart McKee (ex-PwC) and directors John McNicol and Angus Hay. The two firms are linked because Lancaster Capital frequently co-invests with Kelvin Capital (and with Scottish Enterprise's co-investment fund); Tracxn notes the two share a substantial portion of their portfolios. The likeliest explanation for the stub is that Cameron's name was attached to a frequent co-investor rather than his actual firm.

Cameron operates in the Scottish early-stage ecosystem, where syndicates and angel groups (Kelvin Capital, Scottish Enterprise) routinely pool capital into local spinouts. Note that several unrelated people share the name "Hector Cameron" on LinkedIn (including a machine operator in the UK and a managing director at Meyerton Engineering in South Africa); these are distinct individuals and should not be conflated with the Lancaster Capital partner.

Beyond firm-level data in investor databases, little primary biographical detail (education, prior roles, dates) about Cameron is publicly available, and the firm does not appear to maintain a public website. Claims about his specific background should therefore be treated cautiously until confirmed directly.

• Invests at seed stage in UK-based startups, with a documented concentration in Life Sciences and Enterprise Applications.
• Strong life-sciences / medtech bias — the firm's known deals are regenerative medicine and dermatology companies.
• Typically co-invests rather than leading large rounds alone, syndicating with Kelvin Capital and Scottish Enterprise's co-investment fund.
• Backs technology-led, often research-spinout companies with novel, defensible IP — consistent with the broader Glasgow university-spinout deal flow.
• *No directly quoted personal thesis statement from Cameron could be found in public sources.*